Drug Trial Radar · NCT07665723
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
Jul 31, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Conditions
- Active Ulcerative Colitis
Interventions
AfimkibartDrug
Afimkibart will be administered as per the schedule defined in the protocol.
CaffeineDrug
Caffeine will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
WarfarinDrug
Warfarin will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
OmeprazoleDrug
Omeprazole will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
DextromethorphanDrug
Dextromethorphan will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
MidazolamDrug
Midazolam will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
Vitamin KOther
Vitamin K will be administered orally as a rescue medication following warfarin administration per the schedule outlined in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-time Curve Up to Time t (AUC0-t [AUC last]) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
- Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUCinf) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
- Maximum Plasma Concentration (Cmax) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
- Time to Maximum Concentration (Tmax) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
- Elimination Half-life (T1/2) of CYP Probe Substrates (Midazolam, 1-OH-Midazolam, Omeprazole, 5-OH-Omeprazole, Dextromethorphan, Dextrorphan, R-Warfarin, S-Warfarin, Caffeine, and Paraxanthine)Time frame: Up to approximately 13 weeks
- Metabolite-to-parent Area Under the Curve From Time 0 (AUC0-t) Ratio for CYP Probe Substrates (Midazolam and 1-OH-Midazolam, Omeprazole and 5-OH-Omeprazole, Dextromethorphan and Dextrorphan, and Caffeine and Paraxanthine)Time frame: Up to approximately 13 weeks
- Metabolite-to-parent Area Under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf) Ratio for CYP Probe Substrates (Midazolam and 1-OH-Midazolam, Omeprazole and 5-OH-Omeprazole, Dextromethorphan and Dextrorphan, and Caffeine and Paraxanthine)Time frame: Up to approximately 13 weeks
- Metabolite-to-parent Concentration of CYP Probe Substrates (Midazolam and 1-OH-Midazolam, Omeprazole and 5-OH-Omeprazole, Dextromethorphan and Dextrorphan, and Caffeine and Paraxanthine)Time frame: Up to approximately 13 weeks
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Erick H. Alayo Medical Corporation - Gastro SB Clinic
Chula Vista, California · Recruiting
Atlantic Medical Research
Margate, Florida · Recruiting
Allied Biomedical Research Institute, Inc
Miami, Florida · Recruiting
Gastro Health Research
Miami, Florida · Recruiting
UZ Leuven Gasthuisberg
Leuven, Belgium · Recruiting
AZ Delta (Campus Rumbeke)
Roeselare, Belgium · Recruiting
Charite Research Organisation GmbH
Berlin, Germany · Recruiting
Centrum Medyczne "Medis"
Bydgoszcz, Poland · Recruiting
Amicare Sp. z o.o. S.K.
Lodz, Poland · Recruiting
Medrise sp z o.o
Lublin, Poland · Recruiting
Allmedica Badania Kliniczne Sp z o.o. Sp K.
Nowy Targ, Poland · Recruiting
NZOZ Eskulap Pabianice
Pabianice, Poland · Recruiting
SOLUMED Centrum Medyczne
Późna, Poland · Recruiting
Centralny Szpital Kliniczny MSW w Warszawie
Warsaw, Poland · Recruiting
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland · Recruiting
PlanetMed sp. z o.o.
Wroc?aw, Poland · Recruiting
Royal Liverpool University Hospital
Liverpool, United Kingdom · Recruiting
University College London Hospitals
London, United Kingdom · Recruiting
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.